Cocrystal Pharma Financials - Benzinga

Cocrystal Pharma Inc

COCPNASDAQ

Trade with Public

Trade with Public

$1.21

0.076.14%

At close: Sep 18, 5:00 PM EST

$1.21

N/A

After Hours: 4:01 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

Cocrystal Pharma Financials

Cocrystal Pharma (COCP) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Cocrystal Pharma Q2 EPS $(0.23) Misses $(0.17) Estimate, Sales $105.000K

Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.17) by 43.75 percent. This is a 15 percent decrease over losses of $(0.20) per share from

Benzinga Newsdesk

PRO
Cocrystal Pharma Q1 EPS $(0.17) Misses $(0.15) Estimate, Sales $225.000K

Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 26.09 percent increase over losses of $(0.23) per share

Benzinga Newsdesk

PRO
Cocrystal Pharma Q4 EPS $(0.17) Beats $(0.21) Estimate

Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.21) by 19.05 percent. This is a 46.88 percent increase over losses of $(0.32) per share from

Benzinga Newsdesk

PRO
Cocrystal Pharma Q3 EPS $(0.19) Beats $(0.21) Estimate

Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 61.22 percent increase over losses of $(0.49) per share from

Benzinga Newsdesk

PRO
Cocrystal Pharma Q2 EPS $(0.20) Beats $(0.30) Estimate

Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.30) by 33.33 percent. This is a 62.26 percent increase over losses of $(0.53) per share from

Benzinga Newsdesk

PRO
Cocrystal Pharma Q1 EPS $(0.23) Beats $(0.51) Estimate

Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.51) by 54.9 percent. This is a 41.03 percent increase over losses of $(0.39) per share from

Benzinga Newsdesk